Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms (vol 13, 1223282, 2023)

被引：0
|
作者：
Grunwald, Viktor [1 ,2 ]
Powles, Thomas [3 ,4 ]
Eto, Masatoshi [5 ]
Kopyltsov, Evgeny [6 ]
Rha, Sun Young [7 ]
Porta, Camillo [8 ]
Motzer, Robert [9 ]
Hutson, Thomas E. [10 ]
Mendez-Vidal, Maria Jose [11 ]
Hong, Sung-Hoo [12 ]
Winquist, Eric [13 ]
Goh, Jeffrey C. [14 ,15 ]
Maroto, Pablo [16 ]
Buchler, Tomas [17 ,18 ]
Takagi, Toshio [19 ]
Burgents, Joseph E. [20 ]
Perini, Rodolfo [21 ]
He, Cixin [22 ]
Okpara, Chinyere E. [23 ]
McKenzie, Jodi [24 ]
Choueiri, Toni K. [25 ]
机构：
[1] Univ Hosp Essen, Clin Med Oncol, Essen, Germany
[2] Univ Hosp Essen, Clin Urol, Essen, Germany
[3] Queen Mary Univ London, Barts Canc Inst, London, England
[4] Queen Mary Univ London, Royal Free Hosp, London, England
[5] Kyushu Univ, Dept Urol, Fukuoka, Japan
[6] State Inst Healthcare Reg Clin Oncol Dispensary, Omsk, Russia
[7] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Dept Internal Med, Seoul, South Korea
[8] Univ Bari A Moro, Dept Biomed Sci & Human Oncol, Bari, Italy
[9] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[10] Texas Oncol, Med Oncol, Dallas, TX USA
[11] Hosp Univ Reina Sofia, Dept Oncol, Maimonides Inst Biomed Res Cordoba IMIBIC, Cordoba, Spain
[12] Catholic Univ Korea, Seoul St Marys Hosp, Dept Urol, Seoul, South Korea
[13] Univ Western Ontario, Dept Oncol, London, ON, Canada
[14] ICON Res, South Brisbane, Qld, Australia
[15] Univ Queensland, St Lucia, Qld, Australia
[16] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[17] Charles Univ Prague, Dept Oncol, Prague, Czech Republic
[18] Thomayer Univ Hosp, Prague, Czech Republic
[19] Tokyo Womens Med Univ, Dept Urol, Tokyo, Japan
[20] Merck & Co Inc, Global Clin Dev, Rahway, NJ USA
[21] Merck & Co Inc, Clin Res, Rahway, NJ USA
[22] Eisai Inc, Biostat, Nutley, NJ USA
[23] Eisai Ltd, Clin Res, Hatfield, England
[24] Eisai Inc, Clin Res, Nutley, NJ USA
[25] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
来源：
FRONTIERS IN ONCOLOGY | 2024年 / 13卷
关键词：
renal cell carcinoma; lenvatinib; pembrolizumab; sunitinib; bone metastases; liver metastases; lung metastases; sarcomatoid histology;
D O I：
10.3389/fonc.2023.1343027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
    Grunwald, Viktor
    Powles, Thomas
    Eto, Masatoshi
    Kopyltsov, Evgeny
    Rha, Sun Young
    Porta, Camillo
    Motzer, Robert
    Hutson, Thomas E.
    Mendez-Vidal, Maria Jose
    Hong, Sung-Hoo
    Winquist, Eric
    Goh, Jeffrey C.
    Maroto, Pablo
    Buchler, Tomas
    Takagi, Toshio
    Burgents, Joseph E.
    Perini, Rodolfo
    He, Cixin
    Okpara, Chinyere E.
    McKenzie, Jodi
    Choueiri, Toni K.
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [2] Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
    Gruenwald, V.
    Powles, T.
    Eto, M.
    Kopyltsov, E.
    Rha, S. Y.
    Porta, C.
    Motzer, R.
    Hutson, T. E.
    Mendez-Vidal, M. J.
    Hong, S. H.
    Winquist, E.
    Goh, J. C.
    Maroto, P.
    Buchler, T.
    Takagi, T.
    Burgents, J. E.
    Perini, R.
    He, C.
    Okpara, C. E.
    McKenzie, J.
    Choueiri, T. K.
    [J]. ONKOUROLOGIYA, 2024, 20 (01): : 24 - 35
  • [3] Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study
    Eto, Masatoshi
    Takagi, Toshio
    Kimura, Go
    Fukasawa, Satoshi
    Tamada, Satoshi
    Miura, Yuji
    Oya, Mototsugu
    Sassa, Naoto
    Anai, Satoshi
    Nozawa, Masahiro
    Sakai, Hideki
    Perini, Rodolfo
    Yusa, Wataru
    Ikezawa, Hiroki
    Narita, Tomoyuki
    Tomita, Yoshihiko
    [J]. CANCER MEDICINE, 2023, 12 (06): : 6902 - 6912
  • [4] Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): depth of response and efficacy for selected subgroups in the lenvatinib (L) plus pembrolizumab (P) and sunitinib (S) treatment arms
    Gruenwald, Viktor
    Powles, Thomas
    Kopyltsov, Evgeny
    Kozlov, Vadim
    Gordoa, Teresa Alonso
    Eto, Masatoshi
    Hutson, Thomas
    Motzer, Robert
    Winquist, Eric
    Maroto, Pablo
    Keam, Bhumsuk
    Procopio, Giuseppe
    Wong, Shirley
    Melichar, Bohuslav
    Rolland, Frederic
    Oya, Mototsugu
    Rodriguez-Lopez, Karla
    Saito, Kenichi
    Smith, Alan
    Porta, Camillo
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 104 - 105
  • [5] Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): depth of response and efficacy for selected subgroups in the lenvatinib (L) plus pembrolizumab (P) and sunitinib (S) treatment arms
    Gruenwald, V
    Powles, T.
    Kopyltsov, E.
    Kozlov, V
    Alonso, Gordoa T.
    Eto, M.
    Hutson, T.
    Motzer, R.
    Winquist, E.
    Maroto, P.
    Keam, B.
    Procopio, G.
    Wong, S.
    Melichar, B.
    Rolland, F.
    Oya, M.
    Rodriguez-Lopez, K.
    Saito, K.
    Smith, A.
    Porta, C.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 25 - 25
  • [6] Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (LEN) plus pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms.
    Grunwald, Viktor
    Powles, Thomas
    Kopyltsov, Evgeny
    Kozlov, Vadim
    Gordoa, Teresa Alonso
    Eto, Masatoshi
    Hutson, Thomas E.
    Motzer, Robert J.
    Winquist, Eric
    Maroto-Rey, Pablo
    Keam, Bhumsuk
    Procopio, Giuseppe
    Wong, Shirley
    Melichar, Bohuslav
    Rolland, Frederic
    Oya, Mototsugu
    Rodriguez-Lopez, Karla
    Saito, Kenichi
    Smith, Alan D.
    Porta, Camillo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR) a randomised, phase 3 study
    Motzer, Robert
    Porta, Camillo
    Alekseev, Boris
    Rha, Sun Young
    Choueiri, Toni K.
    Mendez-Vidal, Maria Jose
    Hong, Sung-Hoo
    Kapoor, Anil
    Goh, Jeffrey C.
    Eto, Masatoshi
    Bennett, Lee
    Wang, Jinyi
    Pan, Jie Janice
    Saretsky, Todd L.
    Perini, Rodolfo F.
    He, Cixin Steven
    Mody, Kalgi
    Cella, David
    [J]. LANCET ONCOLOGY, 2022, 23 (06): : 768 - 780
  • [8] Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomized, phase 3 study
    Motzer, R.
    Porta, C.
    Alekseev, B.
    Rha, S. Y.
    Choueiri, T. K.
    Mendez-Vidal, M. J.
    Hong, S. H.
    Kapoor, A.
    Goh, J. C.
    Eto, M.
    Bennett, L.
    Wang, J.
    Pan, J. J.
    Saretsky, T. L.
    Perini, R. F.
    He, C. S.
    Mody, K.
    Cella, D.
    [J]. ONKOUROLOGIYA, 2022, 18 (02): : 39 - 57
  • [9] Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC) in the CLEAR study
    Porta, Camillo G.
    Eto, Masatoshi
    Motzer, Robert J.
    De Giorgi, Ugo
    Buchler, Tomas
    Basappa, Naveen S.
    Mendez Vidal, Maria Jose
    Tjulandin, Sergei
    Park, Se Hoon
    Melichar, Bohuslav
    Hutson, Thomas
    Alemany, Carlos
    McGregor, Bradley
    He, Cixin Steven
    Perini, Rodolfo
    Mody, Kalgi
    McKenzie, Jodi
    Ebaid, Basant
    Choueiri, Toni
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 122 - 123
  • [10] Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale
    Grunwald, Viktor
    Powles, Thomas
    Choueiri, Toni K.
    Hutson, Thomas E.
    Porta, Camillo
    Eto, Masatoshi
    Sternberg, Cora N.
    Rha, Sun Young
    He, Cixin S.
    Dutcus, Corina E.
    Smith, Alan
    Dutta, Lea
    Mody, Kalgi
    Motzer, Robert J.
    [J]. FUTURE ONCOLOGY, 2019, 15 (09) : 929 - 941
12345